Articles

Implementing clinical pathways for the management of patients with metastatic non–small-cell lung cancer (NSCLC) led to a dramatic reduction in the total cost of care, while maintaining clinical outcomes, according to a study of 370 patients with NSCLC conducted at Dana-Farber Cancer Institute in Boston.

A brief overview of cancer drugs approved by the FDA between March 15, 2017, and May 30, 2017.

Orlando, FL—Molecular analysis and PD ligand 1 (PD-L1) testing for patients with non–small-cell lung cancer (NSCLC) are critically important. Optimally, multiple biomarker testing should be done at diagnosis, but it also has value before choosing therapy for second-line or later.

MMY1001 is an open-label phase 1b study of daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed patients with multiple myeloma.

The combination of elotuzumab, bortezomib, lenalidomide, and dexamethasone is effective in patients with newly diagnosed multiple myeloma (MM).

A phase 1b study showed that isatuximab is clinically active in patients with relapsed/refractory multiple myeloma.

The combination of bendamustine and pomalidomide with dexamethasone shows promise in patients with relapsed/refractory multiple myeloma (RRMM).

The DSMM XIV study highlights the efficacy of bortezomib versus doxorubicin in combination with lenalidomide and dexamethasone prior to stem-cell transplant in patients with newly diagnosed multiple myeloma.

The Myeloma XI Study analyzed lenalidomide induction and maintenance therapy in transplant-eligible patients with myeloma.